Andrew W.. Stacey

Undergraduate Education: BS, Biostatistics, Brigham Young University
Medical School: MD, Ohio State University
Post Graduate Education: MS, Statistics, Brigham Young University
Internship: Transitional Year Internship, Riverside Methodist Hospital
Residency: Ophthalmology, The University of Michigan Kellogg Eye Center
Fellowship: Ocular Oncology, Moorfields Eye Hospital and St. Bartholomew Hospital
Board Certification: Board Eligible

Memberships: American Academy of Ophthalmology (AAO), International Society of Ocular Oncology (ISOO), Washington Academy of Eye Physicians and Surgeons & Association of Research in Vision and Ophthalmology

Sub Specialty Societies: International Society of Ocular Oncology (ISOO)

Dr. Andrew Stacey grew up in Northeast Ohio. He earned a bachelor’s degree and master's degree in Statistics at Brigham Young University, where he was also a linebacker on the football team. During college, he took two years off school and athletics to volunteer for his church in Northern Italy. He completed his medical degree at The Ohio State University and completed his ophthalmology training at the University of Michigan Kellogg Eye Center. He completed a fellowship in ocular oncology at Moorfields Eye Hospital in London, U.K.

Dr. Stacey is an Associate Professor and Associate Director of Medical Student Education for Research in the Department of Ophthalmology at the University of Washington. He specializes in ocular oncology and cataract surgery. He sees patients with general eye problems, including diabetes and cataracts. His subspecialty focus is intraocular and ocular surface tumors in adults and children. He has worked at a number of large ocular oncology referral centers across the world, including the international retinoblastoma referral center in Siena, Italy, and the renowned Moorfields Eye Hospital ocular oncology unit in London, England. He sees patients with conjunctival tumors, iris tumors, choroidal tumors, metastatic lesions, and retinoblastoma. He has authored many publications and book chapters related to ocular tumors and maintains numerous national and international research collaborations in the field. Dr. Stacey currently lives in Seattle with his wife and three young children. In his free time, he enjoys running, mountain biking, fly fishing and being in the mountains with his family.

Eye Institute at Harborview

Location: Harborview Medical Center 908 Jefferson St., 7th Floor Seattle, WA Clinic Phone: 206-744-2020 Clinic Fax: 206-897-4320

Mailing Address: Box 359608 325 Ninth Ave. Seattle, WA 98104 Academic Phone: 206-543-7250

Additional Offices:

UW Medical Center Oto/Ophthalmology Clinic, 3rd floor 1959 Pacific St. Seattle, WA Clinic Phone: 206-744-2020 Seattle Children's Hospital Ophthalmology Clinic 4800 Sandpoint Way, Ocean 6 Seattle, WA 98105 Clinic Phone: 206-987-2177 Clinic Fax: 206-987-2722

"An appointment with your doctor can be stressful. When your eyes and vision are affected, the stress can be magnified. I enjoy teaching my patients about what I see in their eyes and providing them with information and options, then together we can come up with the best course of action."

2015 Resident Physician Community Service Award, Association of American Medical Colleges (AAMC)

2015 University of Michigan, Resident Teacher of the Year

2014 University of Michigan, Paul Lichter Mentorship Award

2009 Ohio State College of Medicine, Jones Student-Athlete Scholarship

Dr. Stacey specializes in cataract surgery and ocular oncology. He sees patients with conjunctival tumors (papilloma, intraepithelial neoplasia, squamous cell carcinoma, melanoma, lymphoma), adult intraocular tumors (iris melanoma, ciliary body melanoma, choroidal melanoma, intraocular metastasis, intraocular lymphoma, retinal angiomas, choroidal hemangiomas, vasoproliferative tumors of the retina), and pediatric intraocular tumors and vascular abnormalities (retinoblastoma, medulloepithelioma, Coats' disease).

Dr. Stacey’s research interests include emerging therapeutics for patients with choroidal melanomas, novel statistical approaches to medical research and clinical trial design, telemedicine and new technologies for early diagnosis of ocular tumors, and research into retinoblastoma treatments and outcomes.